益智逐瘀颗粒治疗血管性痴呆48例

目的观察益智逐瘀颗粒治疗痰血瘀阻型血管性痴呆的临床疗效。方法将96例血管性痴呆患者随机分为两组,对照组48例给予西药单唾液酸四己糖神经节苷脂钠治疗,治疗组48例在西药单唾液酸四己糖神经节苷脂钠治疗的基础上加服益智逐瘀颗粒,10d为一个疗程,两组均连续治疗2个疗程后判定疗效。结果治疗组总有效率为91.67%,对照组总有效率为64.58%,两组疗效比较,差异有显著性(P0.05)。结论益智逐瘀颗粒治疗痰血瘀阻型血管性痴呆疗效显著。     

中西医结合长疗程治疗强直性脊柱炎临床分析

目的探讨在强直性脊柱炎临床治疗中运用中西医结合方法的临床效果。方法选取我院2013—2016年收治的90例强直性脊柱炎患者作为本次研究对象,按照治疗方式不同将所选病例分为采取中西医结合治疗的观察组与单纯运用西医治疗的对照组,比较两组治疗效果。结果观察组本次治疗总有效率明显高于对照组,差异有统计学意义(P0.05);治疗后两组患者ESR、CRP均有不同程度地降低,但观察组上述两项指标降低的程度显著优于对照组,差异有统计学意义(P0.05)。结论在强直性脊柱炎临床治疗中采取中西医结合治疗临床效果显著,明显降低患者ESR、CRP指标,值得临床推广应用。     

浅针治疗围绝经期失眠症的对照研究

目的观察浅针治疗围绝经期失眠症的临床疗效和睡眠改善情况。方法将60例患者随机分为浅针组和体针组,每组30例,浅针组使用浅针手法刺激山根、额中、镇静、定神、印堂,体针组使用体针疗法刺激神门、内关、百会、安眠,两组均每日治疗1次,共治疗10次,分别于治疗前后以匹兹堡睡眠质量指数(PSQI)评定睡眠状况,并比较两组临床疗效。结果两组治疗后PSQI评分与同组治疗前比较,差异均具有统计学意义(P0.01),治疗后治疗组PSQI评分与对照组比较,差异无统计学意义(P0.05),两组治疗后疗效评定比较差异无统计学意义(P0.05)。结论使用浅针治疗围绝经期失眠症可以和体针发挥一样的疗效,且浅针无创伤、无痛苦、无不良作用,值得临床推广使用。     

食疗配合中药治疗瘀血型胃溃疡的临床疗效

目的对中医食疗配合中医药治疗瘀血型胃溃疡的疗效进行分析和探讨。方法选取我院2013年6月—2015年3月收治的98例瘀血型胃溃疡患者,随机分为观察组和对照组,观察组患者接受中医食疗配合中医药的治疗,对照组患者仅接受中医药治疗,对比临床疗效。结果观察组患者临床治疗总有效率为91.84%,对照组患者临床治疗总有效率为79.59%,观察组患者治疗总有效率显著高于对照组患者,组间比较差异显著(P0.05)。结论中医食疗配合中医药治疗瘀血型胃溃疡疗效显著,可有效提高患者治疗总有效率。     

中西医结合治疗功能性消化不良临床观察

目的评价中西医结合治疗脾虚气滞型功能性消化不良的临床疗效。方法将112例中医辨证为脾虚气滞型的功能性消化不良患者随机分为治疗组和对照组。对照组给予西医规范治疗,治疗组在对照组基础上加用中药治疗。两组疗程均为3周。观察两组患者的症状、体征、疗效。结果治疗后两组患者对比,治疗组患者的症状改善较对照组更为明显。其差异具有统计学意义(P0.05)。结论中医药能更好地改善功能性消化不良患者的临床症状,较单纯西医治疗更能获得满意的疗效。     

石决明散加减方治疗肝经积热型前葡萄膜炎的临床研究

目的观察中药石决明散加减方治疗肝经积热型前葡萄膜炎的临床效果。方法前葡萄膜炎患者60例随机分为两组各30例,对照组采用眼局部治疗,治疗组在对照组的基础上加用中药石决明散加减方中医辨证治疗,对比分析两组治疗效果。结果总有效率:治疗组为86.7%,对照组为76.7%,两组比较差异有统计学意义(P0.05);两组在随访中,复发率治疗组为10.0%,对照组为26.7%,差异有统计学意义(P0.05);中西医结合治疗其疗效优于对照组。结论中药石决明散加减方配合眼局部治疗可以缩短病程,提高疗效,减少复发。     

腮腺复发性多形性腺瘤的临床分析--附22例报告

目的：探讨腮腺多形性腺瘤复发、恶变的原因及临床治疗方法。方法：对22例腮腺多形性腺瘤复发患者进行回顾性分析和追踪调查。结果：多数腮腺多形性腺瘤复发病例肿块呈多灶性（18／22），手术越简单其复发率越高，复发间期越短（P＜0．05）。22人中有7例发生恶变，占31．8％，恶变与初发年龄较大有关（P＜0．05），与手术次数关系不大。末次手术分别采用浅叶切除术，腮腺全切术、扩大切除术，对7例有恶变者于术后辅以放射治疗。术后平均追踪54月，除1例多形性腺瘤恶变者于术后30月时肿瘤复发外，其余均未见复发。结论：不恰当的手术方式是导致腮腺性多形性腺瘤复发的直接原因。     

Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch

Boron Neutron Capture Therapy (BNCT) is a bimodal cancer treatment based on the selective accumulation of 10B in tumors and concurrent irradiation with thermalized neutrons. The short-range, high-LET radiation produced by the capture of neutrons by 10B could potentially control tumor while sparing normal tissue if the boron compound targets tumor selectively within the treatment volume. In previous studies, we proposed and validated the hamster cheek pouch model of oral cancer for BNCT studies, proved that absolute and relative uptake of the clinically employed boron compound boronophenylalanine (BPA) would be potentially therapeutic in this model and provided evidence of the efficacy of in vivo BPA-mediated BNCT to control hamster oral mucosa tumors with virtually no damage to normal tissue. We herein present the biodistribution and pharmacokinetics of a lipophilic, carborane-containing tetraphenylporphyrin (CuTCPH) in the hamster oral cancer model. CuTCPH is a novel, non-toxic compound that may be advantageous in terms of selective and absolute delivery of boron to tumor tissues. For potentially effective BNCT, tumor boron concentrations from a new agent should be greater than 30 ppm and tumor/blood and tumor/normal tissue boron concentration ratios should be greater than 5/1 without causing significant toxicity. We administered CuTCPH intraperitoneally (i.p.) as a single dose of 32 microg/g body weight (b.w.) (10 microg B/g b.w.) or as four doses of 32 microg/g b.w. over 2 days. Blood (Bl) and tissues were sampled at 3, 6, 12, 24, 48, and 72 h in the single-dose protocol and at 1-4 days after the last injection in the multidose protocol. The tissues sampled were tumor (T), precancerous tissue surrounding tumor, normal pouch (N), skin, tongue, cheek and palate mucosa, liver, spleen, parotid gland and brain. The maximum mean B ratios for the single-dose protocol were T/N: 9.2/1 (12h) and T/Bl: 18.1/1 (72 h). The B value peaked to 20.7+/-18.5 ppm in tumor at 24h. The multidose protocol maximum mean ratios were T/N: 11.9/1 (3 days) and T/Bl: 235/1 (4 days). Absolute boron concentration in tumor reached a maximum value of 116 ppm and a mean value of 71.5+/-48.3 ppm at 3 days. The fact that absolute and relative B values markedly exceeded the BNCT therapeutic threshold with no apparent toxicity may confer on this compound a therapeutic advantage. CuTCPH-mediated BNCT would be potentially useful for the treatment of oral cancer in an experimental model.     

行为疗法在语音治疗中的应用研究

目的 为提高语音障碍的治疗效果。应用行为疗法治疗腭咽闭合功能不全型（VPI）患者，方法 20例VPI患者，其中先天性腭咽闭合功能不全5例，咽成形术术后10例，腭成形术术后5例，男性10例，女性10例，年龄4.0-38.4岁，平均年龄17.8。采用行为疗法进行语音治疗，并在治疗前后定量检测汉语语音清晰度和吹气实验。结果 治疗效果满意，治疗后的汉语语音清晰度和吹气实验较治疗前有显著提高。结论 行为疗法是一种行之有效的语音治疗方法，但要注意严格掌握适应证和个体化应用。     

氦-氖激光和深海鱼油联合治疗复发性口腔溃疡的疗效评价

目的 观察氦-氖激光和深海鱼油联合治疗复发性口腔溃疡(RAU)的临床效果。方法 将159名复发性口腔溃疡病人随机分成3组。联合治疗组(以下称联合组):用氦-氖激光局部照射和口服深海鱼油联合治疗;对照1:仅用氦-氖激光局部照射溃疡;对照2:每日早晚各口服深海鱼油1000mg。结果(1)有效率:联合组:88.68％,对照组1:73.59％,对照组2:66.04%。联合组与对照组1或对照组2均有显著的差异(x_1~2=3.95,P<0.05,x~_2=7.76,P<0.05)。(2)平均溃疡期:联合组(4.15±1.36)d,对照组1(4.55±1.41)d,对照组2(6.36±1.44)d,联合组与对照组1或对照组2均有显著的差异(t_1=2.19,P<0.05;t_2=2.35,P<0.05)。(3)疼痛指数:联合组(2.85±1.32),对照组1(3.45±1.49),对照组2(5.66±1.69),联合组与对照组1或对照组2均有显著的差异(t_1=3.07,P<0.01;t_2=2.98,P<0.01)。结论氦-氖激光和深海鱼油联合治疗复发性口腔溃疡取得了较满意的临床效果。